Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of lute...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology Jg. 34; H. 15; S. 1748 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
20.05.2016
|
| Schlagworte: | |
| ISSN: | 1527-7755, 1527-7755 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer.
A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union Against Cancer TNM 1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA ≤ 50 ng/mL, were centrally randomized 1:1 to either RT or RT plus AS started on day 1 of RT. Centers opted for one dose (70, 74, or 78 Gy). Biochemical DFS, the primary end point, was defined from entry until PSA relapse (Phoenix criteria) and clinical relapse by imaging or death of any cause. The trial had 80% power to detect hazard ratio (HR), 0.714 by intent-to-treat analysis stratified by dose of RT at the two-sided α = 5%.
The median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; P < .001, with 319 events), as well as clinical progression-free survival (205 events, HR, 0.63; 95% CI, 0.48 to 0.84; P = .001). In exploratory analysis, no statistically significant interaction between treatment effect and dose of RT could be evidenced (heterogeneity P = .79 and P = .66, for biochemical DFS and progression-free survival, respectively). Overall survival data are not mature yet.
Six months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation. |
|---|---|
| AbstractList | Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer.
A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union Against Cancer TNM 1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA ≤ 50 ng/mL, were centrally randomized 1:1 to either RT or RT plus AS started on day 1 of RT. Centers opted for one dose (70, 74, or 78 Gy). Biochemical DFS, the primary end point, was defined from entry until PSA relapse (Phoenix criteria) and clinical relapse by imaging or death of any cause. The trial had 80% power to detect hazard ratio (HR), 0.714 by intent-to-treat analysis stratified by dose of RT at the two-sided α = 5%.
The median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; P < .001, with 319 events), as well as clinical progression-free survival (205 events, HR, 0.63; 95% CI, 0.48 to 0.84; P = .001). In exploratory analysis, no statistically significant interaction between treatment effect and dose of RT could be evidenced (heterogeneity P = .79 and P = .66, for biochemical DFS and progression-free survival, respectively). Overall survival data are not mature yet.
Six months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation. Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer.PURPOSEUp to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer.A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union Against Cancer TNM 1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA ≤ 50 ng/mL, were centrally randomized 1:1 to either RT or RT plus AS started on day 1 of RT. Centers opted for one dose (70, 74, or 78 Gy). Biochemical DFS, the primary end point, was defined from entry until PSA relapse (Phoenix criteria) and clinical relapse by imaging or death of any cause. The trial had 80% power to detect hazard ratio (HR), 0.714 by intent-to-treat analysis stratified by dose of RT at the two-sided α = 5%.PATIENTS AND METHODSA total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union Against Cancer TNM 1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA ≤ 50 ng/mL, were centrally randomized 1:1 to either RT or RT plus AS started on day 1 of RT. Centers opted for one dose (70, 74, or 78 Gy). Biochemical DFS, the primary end point, was defined from entry until PSA relapse (Phoenix criteria) and clinical relapse by imaging or death of any cause. The trial had 80% power to detect hazard ratio (HR), 0.714 by intent-to-treat analysis stratified by dose of RT at the two-sided α = 5%.The median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; P < .001, with 319 events), as well as clinical progression-free survival (205 events, HR, 0.63; 95% CI, 0.48 to 0.84; P = .001). In exploratory analysis, no statistically significant interaction between treatment effect and dose of RT could be evidenced (heterogeneity P = .79 and P = .66, for biochemical DFS and progression-free survival, respectively). Overall survival data are not mature yet.RESULTSThe median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; P < .001, with 319 events), as well as clinical progression-free survival (205 events, HR, 0.63; 95% CI, 0.48 to 0.84; P = .001). In exploratory analysis, no statistically significant interaction between treatment effect and dose of RT could be evidenced (heterogeneity P = .79 and P = .66, for biochemical DFS and progression-free survival, respectively). Overall survival data are not mature yet.Six months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation.CONCLUSIONSix months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation. |
| Author | Herrera, Fernanda G Scrase, Christopher Bahl, Amit Armstrong, John van der Steen-Banasik, Elzbieta M Bosset, Jean-François Kitsios, Petros Pieters, Bradley Boehmer, Dirk Poortmans, Philip M P Carrie, Christian Villa, Salvador Coens, Corneel Shash, Emad Ben-Yosef, Rahamim Renard, Laurette Collette, Laurence Maingon, Philippe Slot, Annerie Bolla, Michel van den Bergh, Alphonsus C M Sundar, Santhanam |
| Author_xml | – sequence: 1 givenname: Michel surname: Bolla fullname: Bolla, Michel email: mbolla@chu-grenoble.fr organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt. mbolla@chu-grenoble.fr – sequence: 2 givenname: Philippe surname: Maingon fullname: Maingon, Philippe organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 3 givenname: Christian surname: Carrie fullname: Carrie, Christian organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 4 givenname: Salvador surname: Villa fullname: Villa, Salvador organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 5 givenname: Petros surname: Kitsios fullname: Kitsios, Petros organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 6 givenname: Philip M P surname: Poortmans fullname: Poortmans, Philip M P organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 7 givenname: Santhanam surname: Sundar fullname: Sundar, Santhanam organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 8 givenname: Elzbieta M surname: van der Steen-Banasik fullname: van der Steen-Banasik, Elzbieta M organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 9 givenname: John surname: Armstrong fullname: Armstrong, John organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 10 givenname: Jean-François surname: Bosset fullname: Bosset, Jean-François organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 11 givenname: Fernanda G surname: Herrera fullname: Herrera, Fernanda G organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 12 givenname: Bradley surname: Pieters fullname: Pieters, Bradley organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 13 givenname: Annerie surname: Slot fullname: Slot, Annerie organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 14 givenname: Amit surname: Bahl fullname: Bahl, Amit organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 15 givenname: Rahamim surname: Ben-Yosef fullname: Ben-Yosef, Rahamim organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 16 givenname: Dirk surname: Boehmer fullname: Boehmer, Dirk organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 17 givenname: Christopher surname: Scrase fullname: Scrase, Christopher organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 18 givenname: Laurette surname: Renard fullname: Renard, Laurette organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 19 givenname: Emad surname: Shash fullname: Shash, Emad organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 20 givenname: Corneel surname: Coens fullname: Coens, Corneel organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 21 givenname: Alphonsus C M surname: van den Bergh fullname: van den Bergh, Alphonsus C M organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt – sequence: 22 givenname: Laurence surname: Collette fullname: Collette, Laurence organization: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26976418$$D View this record in MEDLINE/PubMed |
| BookMark | eNpN0M9PwjAUB_DGYOSH3j2ZHr0M267dVm9komBIMIBn0q1vMB0ttttB_wr_ZIdg4un7vsknL3mvjzrGGkDompIhZYTcPafzISNUDCM-TIgQZ6hHBYuDOBai82_uor73b4RQnoTiAnVZJOOI06SHvpdb62o8MtrZDRi8bPZ7B96X1mBlNF4oXar60B6sBzz2uaqOvbAOT00NbgcHAsGvn5SbbbAo_Tue2ZaWX6Dxi7O-bgVOlcnB3eMF-KaqPbYFHs8XqxSvXKkqzJiU9BKdF6rycHXKAXp9HK_SSTCbP03T0SzIOYnrQBHONI2ELlQIhZCahYWSEWcAYcIL0JDpvEgiRWSYM8hknEWatJkkGSMtH6Db4969sx8N-Hq9K30OVaUM2MavaZxIEnLJeEtvTrTJ2mPXe1fulPtc_32R_QAkNncX |
| CitedBy_id | crossref_primary_10_3390_cancers13010075 crossref_primary_10_1016_j_ijrobp_2018_12_054 crossref_primary_10_1038_s41585_020_0310_3 crossref_primary_10_1007_s10741_020_09984_2 crossref_primary_10_1001_jamanetworkopen_2021_11092 crossref_primary_10_1002_pros_24349 crossref_primary_10_1007_s00066_019_01476_z crossref_primary_10_1016_j_euf_2019_11_005 crossref_primary_10_1002_cncr_30506 crossref_primary_10_1016_j_prro_2020_09_013 crossref_primary_10_1016_j_brachy_2020_05_007 crossref_primary_10_1097_COC_0000000000001181 crossref_primary_10_1016_j_radonc_2018_06_004 crossref_primary_10_1002_pros_24059 crossref_primary_10_3390_cancers15164159 crossref_primary_10_1093_jjco_hyad019 crossref_primary_10_1038_s41391_022_00496_8 crossref_primary_10_1016_j_ijrobp_2020_01_005 crossref_primary_10_1016_j_ctro_2022_07_008 crossref_primary_10_3389_fonc_2019_01273 crossref_primary_10_1016_j_canrad_2020_06_010 crossref_primary_10_1007_s00066_019_01553_3 crossref_primary_10_1016_j_ijrobp_2021_01_032 crossref_primary_10_1200_PO_24_00605 crossref_primary_10_1016_j_ijrobp_2021_12_005 crossref_primary_10_1259_bjr_20190353 crossref_primary_10_1016_j_canrad_2017_07_045 crossref_primary_10_1038_s41391_024_00829_9 crossref_primary_10_1038_s41391_018_0084_3 crossref_primary_10_1016_j_ijrobp_2021_09_034 crossref_primary_10_1016_j_ijrobp_2018_11_007 crossref_primary_10_1016_j_ijrobp_2021_09_032 crossref_primary_10_1016_j_euo_2020_03_002 crossref_primary_10_1001_jamanetworkopen_2020_0363 crossref_primary_10_1136_bmjopen_2019_030731 crossref_primary_10_1016_j_soncn_2020_151054 crossref_primary_10_2147_RRU_S303215 crossref_primary_10_3390_cancers15133363 crossref_primary_10_1016_j_ijrobp_2021_04_013 crossref_primary_10_1007_s00066_019_01562_2 crossref_primary_10_1016_j_clon_2023_03_018 crossref_primary_10_1200_JCO_2015_66_2320 crossref_primary_10_1016_j_clgc_2021_01_003 crossref_primary_10_3390_cancers11010020 crossref_primary_10_1007_s00345_023_04649_9 crossref_primary_10_1007_s10147_019_01596_7 crossref_primary_10_1016_j_eururo_2017_07_012 crossref_primary_10_1055_a_2539_0734 crossref_primary_10_1016_j_eururo_2022_04_003 crossref_primary_10_1016_j_eururo_2020_11_010 crossref_primary_10_1016_S1470_2045_22_00190_5 crossref_primary_10_1093_annonc_mdx637 crossref_primary_10_1016_j_ijrobp_2018_09_023 crossref_primary_10_1200_JCO_2018_79_3257 crossref_primary_10_1016_j_ejca_2020_10_023 crossref_primary_10_3390_cancers14092226 crossref_primary_10_1016_j_brachy_2021_12_008 crossref_primary_10_1016_j_ctarc_2019_100119 crossref_primary_10_1080_14737140_2016_1218279 crossref_primary_10_1016_j_eururo_2025_07_019 crossref_primary_10_1016_j_urolonc_2021_06_022 crossref_primary_10_1016_j_brachy_2017_04_001 crossref_primary_10_1097_QMH_0000000000000520 crossref_primary_10_1016_j_brachy_2019_01_016 crossref_primary_10_1097_MOU_0000000000001074 crossref_primary_10_1186_s13014_017_0884_y crossref_primary_10_1016_j_ijrobp_2024_02_025 crossref_primary_10_2147_RRU_S243088 crossref_primary_10_1016_j_ijrobp_2018_08_030 crossref_primary_10_1080_14737140_2018_1477595 crossref_primary_10_5301_tj_5000595 crossref_primary_10_1016_j_semradonc_2016_08_003 crossref_primary_10_1097_PPO_0000000000000428 crossref_primary_10_1016_S1470_2045_21_00705_1 crossref_primary_10_1016_j_ijrobp_2023_08_046 crossref_primary_10_1007_s15015_016_2877_3 crossref_primary_10_1259_bjr_20170431 crossref_primary_10_1016_j_urolonc_2017_10_020 crossref_primary_10_1016_j_jaccao_2020_08_011 crossref_primary_10_1038_s41391_024_00811_5 crossref_primary_10_1200_JCO_2017_76_2872 crossref_primary_10_1111_ajco_13108 crossref_primary_10_1016_j_eururo_2022_07_011 crossref_primary_10_1016_j_brachy_2017_08_003 crossref_primary_10_1186_s13014_020_01527_1 crossref_primary_10_3390_cancers13174257 crossref_primary_10_1016_j_clon_2023_03_001 crossref_primary_10_1016_j_ijrobp_2017_02_019 crossref_primary_10_1016_j_canrad_2017_06_010 crossref_primary_10_1007_s12094_020_02437_0 crossref_primary_10_1007_s00761_019_0529_x crossref_primary_10_1097_PPO_0000000000000419 crossref_primary_10_1016_j_canrad_2019_06_018 crossref_primary_10_1097_PPO_0000000000000420 crossref_primary_10_1016_j_eururo_2017_06_027 crossref_primary_10_1080_0284186X_2023_2269600 crossref_primary_10_1200_JCO_2017_76_2005 crossref_primary_10_1007_s00092_016_1266_8 crossref_primary_10_1016_j_ijrobp_2021_12_160 crossref_primary_10_1016_j_prro_2023_04_009 crossref_primary_10_1093_jjco_hyab167 crossref_primary_10_3892_mco_2023_2674 crossref_primary_10_1200_JCO_2016_68_4530 crossref_primary_10_1186_s13014_020_01577_5 crossref_primary_10_1007_s00345_023_04635_1 crossref_primary_10_1016_j_fpurol_2021_09_002 crossref_primary_10_1002_cncr_30093 crossref_primary_10_1007_s11654_016_5279_2 crossref_primary_10_1016_j_ijrobp_2020_06_017 crossref_primary_10_1080_14656566_2020_1803281 crossref_primary_10_1097_PPO_0000000000000209 crossref_primary_10_1016_j_eururo_2017_08_011 crossref_primary_10_1016_j_canrad_2020_03_014 crossref_primary_10_1016_j_clon_2016_09_020 crossref_primary_10_1016_j_brachy_2021_09_001 crossref_primary_10_1093_jnci_djw281 crossref_primary_10_1002_pros_24693 crossref_primary_10_1016_j_fpurol_2024_07_204 crossref_primary_10_1371_journal_pone_0187794 crossref_primary_10_1016_j_clgc_2020_03_017 crossref_primary_10_1055_a_2307_4799 crossref_primary_10_2217_fon_2021_0575 crossref_primary_10_1016_j_ijrobp_2020_11_059 crossref_primary_10_1007_s00345_019_02661_6 crossref_primary_10_1016_j_radonc_2023_109544 crossref_primary_10_1186_s12885_021_08609_7 crossref_primary_10_1002_cncr_31217 crossref_primary_10_1016_j_bulcan_2016_09_015 crossref_primary_10_1007_s11934_017_0698_3 |
| ContentType | Journal Article |
| Copyright | 2016 by American Society of Clinical Oncology. |
| Copyright_xml | – notice: 2016 by American Society of Clinical Oncology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2015.64.8055 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 26976418 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQOH AARDX AAWTL AAYEP ABBLC ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL BYPQX C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YFH YQY 7X8 |
| ID | FETCH-LOGICAL-c407t-a042d165dfa3ef59d23fa9642ee384fedebdcf86a093c2eb97b6d0eb988b209d2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 172 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000375541100011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Thu Oct 02 05:35:05 EDT 2025 Mon Jul 21 05:41:47 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 15 |
| Language | English |
| License | 2016 by American Society of Clinical Oncology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c407t-a042d165dfa3ef59d23fa9642ee384fedebdcf86a093c2eb97b6d0eb988b209d2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://serval.unil.ch/notice/serval:BIB_90CAFB1C78DC |
| PMID | 26976418 |
| PQID | 1789034924 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1789034924 pubmed_primary_26976418 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-05-20 20160520 |
| PublicationDateYYYYMMDD | 2016-05-20 |
| PublicationDate_xml | – month: 05 year: 2016 text: 2016-05-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2016 |
| References | 26976421 - J Clin Oncol. 2016 May 20;34(15):1715-7 |
| References_xml | – reference: 26976421 - J Clin Oncol. 2016 May 20;34(15):1715-7 |
| SSID | ssj0014835 |
| Score | 2.5817807 |
| Snippet | Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1748 |
| SubjectTerms | Adult Aged Aged, 80 and over Androgen Antagonists - therapeutic use Combined Modality Therapy Humans Male Middle Aged Prostate-Specific Antigen - blood Prostatic Neoplasms - mortality Prostatic Neoplasms - therapy Radiotherapy Dosage |
| Title | Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26976418 https://www.proquest.com/docview/1789034924 |
| Volume | 34 |
| WOSCitedRecordID | wos000375541100011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS9xAFB5sleJLtd66rcoRxCfHzW2SSV9E1hUpuoZ1hX1bMpkZXCyJdXYL9lf0J_ecJLJPguBLIDAJgfPlzHfmXD7GDpExJKbAsEQhl-BRriyXUaR5rFJV2MTDYK5WLblKBgM5HqdZe-Dm2rLKF59YO2pdFXRG3vWpY5NG6UWnj785qUZRdrWV0PjAlkOkMoTqZLzIIkSyFtgk5VZkkUK0aUoERvdn74bqusRJHJ1IT4jXCWa90VysvfcT19nnlmLCWYOJL2zJlBvs03WbRN9gR1kzrvr5GEaL7it3DEeQLQZZP2-yf7f3SM6Bah4rxBmQAmhTNltCXmoY0lwDMiycV85A36G9m3tkwlCfNdaNKTPD6_VUU8KHU_cAV7SDTv8aDRl1neAK6BH8nn7A0Lj5r5mDykL_ZjjqwYh-EQhwQ_O32N1Ff9S75K2CAy8wUJzxHF2C9mOhbR4aK1IdhDZPMeQxJpSRNdooXVgZ514aFoFRaaJijfhIpVSBh8u32ceyKs1XBoUUyhdE5wS-2-o8kSb1rRCKBg6JuMMOXowywT-E0h55aaq5myzM0mE7jWUnj80oj0kQIx2LfPntDU9_Z6uImJhKBwJvly1b9A9mj60Uf2ZT97RfQw-vg-z6Pwsk4_k |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Short+Androgen+Suppression+and+Radiation+Dose+Escalation+for+Intermediate-+and+High-Risk+Localized+Prostate+Cancer%3A+Results+of+EORTC+Trial+22991&rft.jtitle=Journal+of+clinical+oncology&rft.au=Bolla%2C+Michel&rft.au=Maingon%2C+Philippe&rft.au=Carrie%2C+Christian&rft.au=Villa%2C+Salvador&rft.date=2016-05-20&rft.eissn=1527-7755&rft.volume=34&rft.issue=15&rft.spage=1748&rft_id=info:doi/10.1200%2FJCO.2015.64.8055&rft_id=info%3Apmid%2F26976418&rft_id=info%3Apmid%2F26976418&rft.externalDocID=26976418 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |